Oppenheimer Asset Management Inc. Sells 3,192 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Oppenheimer Asset Management Inc. trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 23.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 10,168 shares of the medical research company’s stock after selling 3,192 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in IQVIA were worth $1,998,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Private Trust Co. NA boosted its position in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co boosted its position in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares during the last quarter. Howard Capital Management Inc. boosted its position in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares during the last quarter. Huntington National Bank boosted its position in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 56 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IQV has been the topic of a number of analyst reports. Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Bank of America cut their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Truist Financial reissued a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Stock Performance

IQV opened at $188.89 on Monday. The business’s 50-day moving average price is $199.13 and its two-hundred day moving average price is $214.65. IQVIA Holdings Inc. has a 1 year low of $184.66 and a 1 year high of $261.73. The company has a market capitalization of $33.26 billion, a price-to-earnings ratio of 25.19, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity

In related news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.